{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:07:58Z","timestamp":1789178878973,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chronic spontaneous urticaria (CSU) is a relapsing inflammatory skin disease associated with substantial symptom burden and repeated healthcare use. Omalizumab is recommended for patients whose disease remains uncontrolled despite second-generation H1-antihistamines, yet large-scale data describing its use in routine care remain limited, particularly in Latin America. The objective of this study is to characterize patients initiating omalizumab for CSU in a large Brazilian healthcare system and examine treatment patterns, healthcare utilization, and concomitant medication use before and after treatment initiation. We conducted a population-based retrospective cohort study using the institutional data lake of a nationwide integrated healthcare organization covering more than 8.9 million beneficiaries. Patients with CSU initiating omalizumab between January 2020 and December 2025 were identified from administrative authorization records linked to clinical and healthcare utilization data. The index date was the first administrative authorization for omalizumab. The primary longitudinal analysis compared healthcare utilization during the 12\u00a0months before and after the index date. Omalizumab dosing patterns, treatment exposure, concomitant medication use, and changes in healthcare utilization were assessed. Negative binomial regression was used in sensitivity analyses to estimate incidence rate ratios. The cohort included 492 patients; the mean age was 41.3\u2009\u00b1\u200913.5\u00a0years and 394 (80.1%) were women. Among 472 patients with available dosing information, 4614 omalizumab administrations were recorded, with doses ranging from 150 to 600\u00a0mg and a median of nine treatment cycles per patient. In the 12-month paired analysis (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009429), mean outpatient visits increased from 5.10 to 10.31 per patient after treatment initiation (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001; IRR, 2.021;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Emergency department use did not change significantly (2.71 vs 2.45 visits per patient;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.291; IRR, 0.907;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.191), nor did hospitalizations (0.07 vs 0.08 per patient;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.816; IRR, 1.065;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.797). Recorded concomitant prescriptions declined from 541 in the pre-index period to 193 in the post-index period. Among patients evaluable for the guideline-concordance analysis, 95.1% were not receiving chronic treatment classified as non-recommended by the study definition. In this nationwide cohort from a Brazilian integrated healthcare system, omalizumab initiation coincided with a change in the pattern of recorded healthcare use for CSU: outpatient contacts increased substantially, whereas emergency department visits and hospitalizations remained statistically stable, and recorded concomitant prescribing declined. Because the study was observational and relied on administrative data without validated measures of disease activity or a concurrent comparator group, these findings describe patterns of care within this healthcare system rather than the clinical effectiveness of omalizumab or its causal impact on healthcare utilization, and extrapolation beyond the Brazilian supplementary healthcare setting studied here should be made with caution.\n                  <\/jats:p>","DOI":"10.1007\/s00210-026-05893-7","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:29:50Z","timestamp":1789176590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and healthcare utilization following omalizumab initiation in chronic spontaneous urticaria: a nationwide Brazilian cohort study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-3196","authenticated-orcid":false,"given":"Jose Arnaldo","family":"Shiomi da Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno Cordeiro","family":"Porto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua Faldini Pinheiro","family":"Koren de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara Goldenstein","family":"Schainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Rodolfo Egydio","family":"de Cerqueira C\u00e9sar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Augusto Lima","family":"de Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Hugo Ovani","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Afonso","family":"da Silva Sardenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"issue":"23","key":"5893_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237482","volume":"12","author":"A Barzilai","year":"2023","unstructured":"Barzilai A, Baum A, Ben-Shoshan M, Tzanani I, Hakroush R, Coster D, Solomon M, Greenberger S (2023) Epidemiological and clinical characteristics of adult and pediatric patients with chronic spontaneous urticaria. J Clin Med 12(23):7482. https:\/\/doi.org\/10.3390\/jcm12237482","journal-title":"J Clin Med"},{"key":"5893_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134547","volume":"14","author":"S Boussaid","year":"2025","unstructured":"Boussaid S, Dhahri R, Rahmouni S, Ceylan H\u0130, Hassayoun M, Abbes M, Zouaoui K, Dergaa I, Rekik S, Boussaid N et al (2025) Impact of biologic drugs on comorbidity outcomes in rheumatoid arthritis: a systematic review. J Clin Med 14:4547. https:\/\/doi.org\/10.3390\/jcm14134547","journal-title":"J Clin Med"},{"issue":"5","key":"5893_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/jdv.20176","volume":"39","author":"S Cazzaniga","year":"2025","unstructured":"Cazzaniga S, Heidemeyer K, Zahn CA, Seyed Jafari SM, Sauter TC, Naldi L, Borradori L (2025) Dermatological emergencies and determinants of hospitalization in Switzerland: a retrospective study. J Eur Acad Dermatol Venereol 39(5):1001\u20131010. https:\/\/doi.org\/10.1111\/jdv.20176","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"5893_CR4","first-page":"141","volume":"24","author":"C Dressler","year":"2024","unstructured":"Dressler C, Nast A, Maurer M (2024) Evidence-based management of chronic spontaneous urticaria: update on guidelines and unmet needs. Curr Opin Allergy Clin Immunol 24(2):141\u2013148","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"5893_CR5","first-page":"e85","volume":"44","author":"LF Ensina","year":"2023","unstructured":"Ensina LF, Criado PR, Chong Neto HJ, Abreu A, Sol\u00e9 D (2023) Chronic spontaneous urticaria in Latin America: clinical characteristics and treatment patterns. Allergy Asthma Proc 44(4):e85\u2013e93","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"5893_CR6","volume":"16","author":"A Gim\u00e9nez-Arnau","year":"2023","unstructured":"Gim\u00e9nez-Arnau A, Ensina LF, Sussman G, Abuzakouk M, Metz M, Maurer M (2023) Impact of omalizumab on healthcare resource utilization in chronic spontaneous urticaria: real-world evidence. World Allergy Organ J 16(6):100789","journal-title":"World Allergy Organ J"},{"issue":"4","key":"5893_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3174\/ajnr.A4696","volume":"37","author":"JA Hirsch","year":"2016","unstructured":"Hirsch JA, Nicola G, McGinty G, Liu RW, Barr RM, Chittle MD, Manchikanti L (2016) ICD-10: history and context. AJNR Am J Neuroradiol 37(4):596\u2013599. https:\/\/doi.org\/10.3174\/ajnr.A4696","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"5893_CR8","first-page":"1285","volume":"78","author":"M Maurer","year":"2023","unstructured":"Maurer M, Metz M, Staubach P, Weller K, Krause K, Magerl M et al (2023) Omalizumab for the treatment of chronic spontaneous urticaria: real-world effectiveness and safety. Allergy 78(5):1285\u20131296","journal-title":"Allergy"},{"issue":"1","key":"5893_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-2198(22)01258-2","volume":"11","author":"SS Saini","year":"2023","unstructured":"Saini SS, Kaplan AP, Bernstein JA, Church MK, Maurer M (2023) Chronic spontaneous urticaria: pathophysiology, disease burden, and emerging treatment strategies. J Allergy Clin Immunol Pract 11(1):15\u201327","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"5893_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40259-014-0084-3","volume":"28","author":"F Spandonaro","year":"2014","unstructured":"Spandonaro F, Ayala F, Berardesca E, Chimenti S, Girolomoni G, Martini P, Peserico A, Polistena B, Puglisi Guerra A, Vena GA, Altomare G, Calzavara Pinton P (2014) The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs 28(3):285\u201395. https:\/\/doi.org\/10.1007\/s40259-014-0084-3","journal-title":"BioDrugs"},{"issue":"9","key":"5893_CR11","first-page":"2500","volume":"78","author":"P Staubach-Renz","year":"2023","unstructured":"Staubach-Renz P, Metz M, Wedi B, Church MK, Maurer M (2023) Psychological burden and quality of life impairment in chronic spontaneous urticaria. Allergy 78(9):2500\u20132510","journal-title":"Allergy"},{"issue":"2","key":"5893_CR12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/jdv.19628","volume":"38","author":"G Sussman","year":"2024","unstructured":"Sussman G, Abuzakouk M, Bindslev-Jensen C, Weller K, Metz M, Maurer M (2024) Optimizing omalizumab treatment in chronic spontaneous urticaria: dose, duration, and discontinuation strategies. J Eur Acad Dermatol Venereol 38(2):247\u2013256","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"5893_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13223-023-00802-6","volume":"19","author":"SF Thomsen","year":"2023","unstructured":"Thomsen SF, Pritzier EC, Anderson CD, Rerknimitr P, Maurer M (2023) Comorbidities and healthcare utilization in patients with chronic spontaneous urticaria. Allergy Asthma Clin Immunol 19(1):45","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"5893_CR14","first-page":"1","volume":"66","author":"K Weller","year":"2024","unstructured":"Weller K, Church MK, Kalogeromitros D, Maurer M (2024) Chronic spontaneous urticaria: current treatment paradigms and real-world outcomes. Clin Rev Allergy Immunol 66(1):1\u201315","journal-title":"Clin Rev Allergy Immunol"},{"issue":"20","key":"5893_CR15","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053","journal-title":"JAMA"},{"issue":"3","key":"5893_CR16","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/all.15090","volume":"77","author":"T Zuberbier","year":"2022","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D et al (2022) The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 77(3):734\u2013766","journal-title":"Allergy"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05893-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05893-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05893-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:29:52Z","timestamp":1789176592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05893-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":16,"alternative-id":["5893"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05893-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"22 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have reviewed and approved the manuscript for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical trial was approved in Plataforma Brasil under number 96939326.0.0000.5450.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}